Enlitic Inc (ENL), an ASX-listed company, is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers.
| ASX Code | ENL |
| Website | N/A |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 5 |
| ENL Share Price | $0.007 |
| Day High | $0.007 |
| Day Low | $0.007 |
| Last Close | $0.007 |
| ENL Share Price Movement | - ( No change ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Enlitic Inc (ENL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$19.98 | -$2.70 | -78.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$24.51 | -$12.90 | -97.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$22.74 | -$474.90 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| 4DMedical Limited (4DX) | $2,160M | 0.3304 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Enlitic Inc (ENL) | $6M | -0.7883 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $17,007M | 0.3919 | 0.2545 | 0.2962 | 147.8565 | 117.8613 | 90.9289 | 0.34% | 0.43% | 0.57% |
| Name | Position | Start Date |
|---|---|---|
| Mr Michael Karl-Gerhard Sistenich | Chief Executive Officer, Executive Director | 1 Nov 2018 |
| Mr Lawrence Bernard Gozlan | Non-Executive Chairman, Non-Executive Director | 23 Sep 2019 |
| Mr Sergio Duchini | Non-Executive Director | 13 Dec 2023 |
| Ms Lisa Pettigrew | Non-Executive Director | 4 Mar 2024 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 10 Feb 2026 | SISTENICH, Michael | Issued | Convertibles | 100,000 | $1.000 | $100,000.000 |
| 10 Feb 2026 | DUCHINI, Sergio | Issued | Convertibles | 25,000 | $1.000 | $25,000.000 |
| 13 Jun 2025 | SISTENICH, Michael | Issued | Indirect Shares | 1,250,000 | $0.040 | $50,000.000 |
See all changes in directors' interest & trades for Enlitic Inc (ENL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Darren Stuart Scotti | Chief Financial Officer,Company Secretary |
| Steve Rankin | Chief Strategy Officer |
| Dan Kozimor | Chief Technology Officer |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Enlitic Inc (ENL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 161,999,982 (19.44%) | J P Morgan Nominees Australia Pty Limited |
| 115,893,602 (13.91%) | Citicorp Nominees Pty Limited |
| 26,250,000 (3.15%) | Jagen Pty Ltd |
| Date | Event |
|---|---|
| 26 February 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
| 26 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.